Systematic review: value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma (brief report)
Fiche publication
Date publication
mars 2008
Auteurs
Membres identifiés du Cancéropôle Est :
Pr CONROY Thierry
Tous les auteurs :
Becouarn Y, Guillo S, Artru P, Assenat E, Bosset JF, Conroy T, Francois E, Taieb J, Touboul E
Lien Pubmed
Résumé
Introduction: The program "Standards, Options and Recommendations" (SOR) in oncology, initiated in 1993 by the French Federation of Cancer Centers (FNCLCC, is conducted in collaboration with public and private clinicians, professional associations, learned societies and the French National Cancer Institute. Its aims are to develop clinical practice guidelines (CPG), health technology assessment reports and systematic literature reviews. In this context, the SOR have developed a systematic review to evaluate the value of perioperative chemotherapy in the management of resectable rectal adenocarcinoma. Results of this review have been validated by the members of the National Thesaurus of Gastrointestinal Cancer (TNCD). Methods: Results of a systematic literature search using Medline(R) and Embase(R) (from 1996/01 to 2007/10) were completed by a survey of evidence-based medicine websites. All phase III randomized trials and systematic reviews comparing surgery (alone or associated with adjuvant therapy) to the same treatment plus chemotherapy, or comparing different perioperative chemotherapy modalities in patients with resectable rectal adenocarcinoma, were included in the study. The quality and clinical relevance of the trials were evaluated using validated checklists, allowing to associate each result with its level of evidence. Data synthesis was performed taking into account both efficacy and toxicity outcomes for each intervention. Finally, research recommendations were formulated. Results: Of 29 studies meeting the selection criteria, 19 were included after critical methodological and clinical appraisal. As compared with preoperative radiotherapy, preoperative chemoradiotherapy with 5-fluorouracil and folinic acid does not improve overall or relapse-free survivals but decreases local recurrence rates. Postoperative chemotherapy with 5-fluorouracil and folinic acid does not improve overall or relapse-free survivals, whether the patients received preoperative radiotherapy or preoperative chemoradiotherapy, whereas it seems to decrease local recurrence rates after preoperative radiotherapy but not after preoperative chemoradiotherapy. As compared with postoperative chemoradiotherapy, preoperative chemoradiotherapy with continuous infusion of 5-fluorouracil does not improve overall or relapse-free survivals, but decreases local recurrence rates as well as acute and long-term toxicities. In the absence of preoperative radiotherapy, fluoropyrimidine-based postoperative chemotherapy improves both overall and relapse-free survivals and decreases local recurence rates. Conclusion: Preoperative chemoradiotherapy reduces the risk of local recurrence as compared with preoperative radiotherapy or postoperative chemoradiotherapy.
Référence
Oncologie. 2008 Mar;10(3):226-32